Mineralys Therapeutics Confirms FDA NDA Acceptance for Lorundrostat with December 2026 PDUFA Date, Reports Strong Cash Position
MLYS has more than doubled off its 52-week low of $10.44.
Summary
Mineralys Therapeutics filed its annual 10-K, confirming FDA acceptance of its NDA for lorundrostat for hypertension with a PDUFA date of December 22, 2026, and reporting a robust cash position of $656.6 million, providing over 12 months of runway.
Key Events · Product Development and Regulatory · MLYS
-
FDA Accepts NDA for Lorundrostat
The FDA accepted the New Drug Application (NDA) for lorundrostat for the treatment of hypertension, setting a PDUFA target action date of December 22, 2026. This follows successful Phase 3 Launch-HTN and Phase 2 Advance-HTN trials.
-
Strong Cash Position and Runway
The company ended December 31, 2025, with $656.6 million in cash, cash equivalents, and investments, which is expected to fund operations for at least the next 12 months.
-
Positive CKD Trial Results
The Phase 2 Explore-CKD trial demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure and urinary albumin creatinine ratio (UACR) in patients with hypertension and chronic kidney disease.
-
Mixed OSA Trial Results
The Phase 2 Explore-OSA trial did not meet its primary endpoint of reducing the apnea-hypopnea index, but it did show clinically meaningful reductions in blood pressure.
Analysis · MLYS · Life Sciences
This annual report provides a comprehensive update on Mineralys Therapeutics' financial health and pipeline progress. The most significant news is the FDA's acceptance of the New Drug Application (NDA) for lorundrostat for hypertension, with a Prescription Drug User Fee Act (PDUFA) target action date of December 22, 2026. This marks a critical step towards potential market approval and commercialization for their lead product candidate. The company also reported a strong cash position of $656.6 million as of December 31, 2025, which is projected to fund operations for at least the next 12 months, providing crucial financial stability for a pre-revenue biotech. While the Phase 2 Explore-OSA trial did not meet its primary endpoint, the observed blood pressure reductions still offer some positive data. The disclosure of new Rule 10b5-1 trading plans by key insiders is a routine event for managing executive compensation and is not an immediate signal of a change in company fundamentals. Investors should focus on the upcoming PDUFA date and the company's commercialization strategy.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1052 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MLYS was trading at $26.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $10.44 to $47.65. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.